Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06571474 Sponsor: Bettina Mittendorfer Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06571474
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 70 years old
  • People who are not currently pregnant or breastfeeding
  • People whose weight has been stable and who have not been doing regular exercise before enrolling
  • People who do not use tobacco products, drink excessive amounts of alcohol, take dietary supplements, or take medications known to affect blood sugar or fat levels in the blood (with some exceptions for people in the Type 2 Diabetes group)
  • People with no significant problems affecting major organs or serious conditions such as severe chronic kidney disease or cancer
  • People who fit into one of the four specific groups below:

Lean group — People with a BMI between 18.5 and 24.9, normal liver fat levels (below 5%), normal fasting blood sugar (below 100 mg/dL), normal blood sugar after a sugar drink test (below 140 mg/dL), and a normal HbA1c blood test result (below 5.7%)

Metabolically normal obesity (MNO) group — People with a BMI between 30.0 and 44.9, normal liver fat levels (below 5%), normal fasting blood sugar (below 100 mg/dL), normal blood sugar after a sugar drink test (below 140 mg/dL), and a normal HbA1c result (below 5.7%)

Metabolically abnormal obesity with insulin resistance and fatty liver disease group — People with a BMI between 30.0 and 44.9, elevated liver fat levels (above 7.5%), mildly elevated fasting blood sugar (100–125 mg/dL), elevated blood sugar after a sugar drink test (140–199 mg/dL), and an HbA1c result in the pre-diabetes range (5.7%–6.3%)

Metabolically abnormal obesity with Type 2 Diabetes group — People with a BMI between 30.0 and 44.9 who have a clinical diagnosis of Type 2 diabetes, or who have significantly elevated fasting blood sugar, or elevated blood sugar after a sugar drink test, or an HbA1c above 6.4% (confirm specific medication requirements with trial site)


Who may not be able to join:

  • People who do not meet all of the inclusion criteria listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bettina Mittendorfer, University of Missouri-Columbia

Phone: 573-882-7619

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bettina Mittendorfer
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insulin sensitivity; 24-hour plasma glucose concentration; Macrophage isolation in adipose tissue biopsy; Macrophage isolation in skeletal muscle tissue

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov